N/A N=142 A Pilot Study to Evaluate the BodyLogic TM System (Mentor) in Augmentation Mammaplasty
Breast Augmentation · Breast Reconstruction
Primary: Reoperation Rates — 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=171 Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 14 Weeks Between Treatment Groups — -0.83; 0.14 percentage of glycosylated haemoglobin
Phase 1 N=22 Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT
Cholestasis · Primary Sclerosing Cholangitis · Primary Biliary Cirrhosis
Primary: Percentage of Participants in Whom we Could Quantify Hepatic Transport of 11C-CSar — 100; 100 percentage of participants
N/A N=66 Evaluation of a New Silicone Hydrogel Contact Lens
Myopia
Primary: Visual Acuity — -0.083; -0.085; -0.084; -0.078 logMAR
Phase 4 N=506 A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic
Dyslipidemias · Cardiovascular Diseases · Hypertriglyceridemia
Primary: Percentage of Triglyceride (TG) Change — -38.12 percentage of TG change
Phase 3 N=210 Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures
Epilepsy
Primary: Evaluate the Safety of USL255 Through the Collection of Adverse Events and Clinical Laboratory Evaluations — 210; 146; 102; 15 participants
Phase 2 N=41 D-cycloserine in the Management of Chronic Low Back Pain
Low Back Pain · Pain
Primary: Change in Numeric Rating Scale (NRS-11) — -2.47; -1.55 units on a scale
N/A N=200 Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Meibomian Gland Dysfunction · Dry Eye
Primary: Stage 1 Mean Change in Total Meibomian Gland Score From Baseline to 3 Months — 11.6; 4.5 units on a scale — p=<0.0001
Phase 4 N=15 Abilify as an Adjunctive Treatment for Refractory Depression
Depressive Disorder, Major
Primary: Hamilton Depression Rating Scale (HDRS) — 7 participants — p=<.001
Phase 2 N=215 Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System
Patients Who Participated in an Intravitreal Brimo PS DDS® Study
Primary: Number of Patients With No Visible Implants in the Study Eye — 14; 37; 26; 35 Patients
Phase 4 N=22 A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia
Fibromyalgia
Primary: Pain Threshold at Baseline — 2.7333; 2.583 kg/cm^2
N/A N=175 eSET Plus Single Embryo Cryotransfer vs Double Embryo Transfer
Infertility · Pregnancy, Multiple
Primary: Clinical Pregnancy Rate — 44.0; 37.4 percentage of pregnancy per transfer
Phase 3 N=60 Administration of Two Injections for Multiple Dupuytren's Contractures
Dupuytren's Contracture
Primary: Percent Change From Baseline in Total Fixed Flexion — 75.5 percentage of contracture change
Phase 4 N=52 Retreatment of Recurrent Dupuytren's Contractures
Dupuytren's Disease
Primary: Clinical Success — 64.5; 45.0 percentage of particpants
Phase 2 N=52 Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Recurrent Neuroblastoma
Primary: Number of Patients With Unacceptable Dose Limiting Toxicities (DLTs) — 1; 2; 9; 18 participants